(Alliance News) - Angle PLC on Wednesday noted positive results from a study of its Parsortix system in small cell lung cancer.Parsortix is Angle's liquid biopsy technology, meaning it Read More
(Alliance News) - Liquid biopsy firm Angle PLC said Thursday the first patients for its ovarian cancer test study have been enrolled ahead of anticipated completion early in 2020.The study Read More
(Alliance News) - Angle PLC on Monday said one of its leading customers, the Disseminated Cancer Cell Network, has published new results of work done to develop a "robust, reliable and for of Read More
(Alliance News) - Angle PLC on Friday said its Parsortix system has been successfully used as a liquid biopsy to investigate an immunotherapy target in lung cancer.Shares in Angle were up a Read More
LONDON (Alliance News) - Angle PLC on Wednesday announced positive results from a study evaluating the ability of its Parsortix and HyCEAD Ziplex platforms to test for ovarian cancer.The to Read More
LONDON (Alliance News) - Liquid biopsy firm Angle PLC on Friday said its Parsortix system has been used in "groundbreaking" cancer research.The research showed the first the time Read More
LONDON (Alliance News) - Angle PLC on Thursday said its ParsortixTM system was used by the University of Texas MD Anderson Cancer Center to develop a new technique for assessing the metastatic of Read More
LONDON (Alliance News) - Liquid biopsy firm Angle PLC on Friday said a "leading" customer has set up a multi-centre study using its Parsortix system.The study is being carried out Read More
LONDON (Alliance News) - Angle PLC on Thursday said it has completed enrolment for a US study of its Parsortix biopsy technology in metastatic breast cancer.All of the 400 subjects required Read More
LONDON (Alliance News) - Angle PLC on Thursday said it has enrolled the first patients in an ovarian cancer verification study, after receiving ethics approval.The study will be divided a a Read More
LONDON (Alliance News) - Angle PLC on Thursday reported a widened interim loss on an increase operating costs.In the six months to October 31, the tumour cell researcher said its pretax to Read More
LONDON (Alliance News) - Angle PLC shares spiked late Thursday afternoon after the company said its Partsortix system will be used in "ground-breaking" new cancer research.Shares Read More
LONDON (Alliance News) - Liquid biopsy company ANGLE PLC said on Monday it has agreed to acquire the remaining shares in US subsidiary ANGLE North America Inc it does not own from Parsotix Georgi Read More
